As of 2024-12-12, the Relative Valuation of Genomic Vision SA (GV.PA) is (0.50) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.00 EUR, the upside of Genomic Vision SA based on Relative Valuation is -27931.8%.
The range of the Relative Valuation is (0.44) - (0.50) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.8x - 22.2x | 18.2x |
| Forward P/E multiples | 15.8x - 18.3x | 18.2x |
| Fair Price | (0.44) - (0.50) | (0.50) |
| Upside | -24322.9% - -28054.2% | -27931.8% |
| Date | P/E |